Roghani Farshad, Mehrabi Koushki Ali, Nezarat Negin, Saleki Mohammad
Assistant Professor, Department of Cardiology, Isfahan University of Medical Sciences, Isfahan, Iran.
ARYA Atheroscler. 2013 Jun;9(4):263-7.
Increased incidence of cardiovascular diseases, especially coronary artery disease (CAD), during recent decades shows this disease entity to be the leading cause of death in the world. On the other hand many successes were achieved in the treatment of these diseases with new technology, which has its own side effects and threats for the patient. Among these new strategies is percutaneous coronary intervention (PCI), especially with stent implantation. Although coronary stents are effective in the treatment of dissection and prevention of restenosis, many side effects and even death have been observed, from 5-10% per year. Some studies showed that there is a relation between high sensitivity C-reactive protein (hs-CRP), as a laboratory marker for early detection of thrombosis and/or restenosis, and early complications of percutaneous coronary intervention. The aim of this study is to evaluate hs-CRP level in patients after PCI and to investigate if this can be a prognostic value for detection of early complication.
This is a descriptive, analytical study done in Shahid Chamran Hospital (Isfahan, Iran) in 2011-2012. 87 patients who had undergone PCI were studied. Their hs-CRP level was measured before and after the study. Moreover, early stent complications were detected during the first 24 hours after insertion. The data was recorded in a researcher-constructed checklist and analyzed by SPSS for Windows 20.
The mean ± SD of hs-CRP level in patients with and without complication were 1.36 ± 0.97 and 3.09 ± 1.8, respectively. According to Student's t-test, the hs-CRP level in patients with early complications was higher than patients without early complications of stent implantation; the difference was statistically significant (P < 0.001).
The hs-CRP serum concentrations of patients with, and without early stent complications were significantly different. According to the control diseases center (CDC) guideline, patients with a high level of hs-CRP need special care and attention.
近几十年来，心血管疾病，尤其是冠状动脉疾病（CAD）的发病率不断上升，表明该疾病实体是全球主要的死亡原因。另一方面，新技术在这些疾病的治疗中取得了许多成功，但这些新技术也有其自身的副作用，并对患者构成威胁。这些新策略包括经皮冠状动脉介入治疗（PCI），尤其是支架植入术。尽管冠状动脉支架在治疗夹层和预防再狭窄方面有效，但每年仍观察到5%至10%的副作用甚至死亡。一些研究表明，作为早期检测血栓形成和/或再狭窄的实验室标志物，高敏C反应蛋白（hs-CRP）与经皮冠状动脉介入治疗的早期并发症之间存在关联。本研究的目的是评估PCI术后患者的hs-CRP水平，并调查其是否可作为检测早期并发症的预后指标。
这是一项于2011年至2012年在伊朗伊斯法罕的沙希德·查姆兰医院进行的描述性分析研究。研究了87例接受PCI的患者。在研究前后测量他们的hs-CRP水平。此外，在支架植入后的头24小时内检测早期支架并发症。数据记录在研究人员编制的检查表中，并使用SPSS for Windows 20进行分析。
有并发症和无并发症患者的hs-CRP水平平均值±标准差分别为1.36±0.97和3.09±1.8。根据学生t检验，早期并发症患者的hs-CRP水平高于无早期支架植入并发症的患者；差异具有统计学意义（P<0.001）。
有早期支架并发症和无早期支架并发症患者的hs-CRP血清浓度存在显著差异。根据疾病控制中心（CDC）指南，hs-CRP水平高的患者需要特别护理和关注。
